LON:SHP - Shire Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
GBX 4,199 -19.00 (-0.45 %)
(As of 05/20/2018 01:42 PM ET)
Previous CloseGBX 4,199
Today's RangeGBX 4,182 - GBX 4,230
52-Week RangeGBX 2,940.50 - GBX 5,021
Volume2.83 million shs
Average Volume3.14 million shs
Market Capitalization£29.14 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Shire (LON:SHP)

Shire logoShire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Receive SHP News and Ratings via Email

Sign-up to receive the latest news and ratings for SHP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:SHP
CUSIPN/A
Phone+353-1-6096000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins16.73%
Return on Equity8.11%
Return on Assets4.11%

Miscellaneous

EmployeesN/A
Outstanding Shares908,640,000

Shire (LON:SHP) Frequently Asked Questions

What is Shire's stock symbol?

Shire trades on the London Stock Exchange (LON) under the ticker symbol "SHP."

How often does Shire pay dividends? What is the dividend yield for Shire?

Shire announced a dividend on Wednesday, February 14th. Investors of record on Thursday, March 8th will be given a dividend of GBX 21.46 per share on Tuesday, April 24th. This represents a yield of 0.67%. The ex-dividend date is Thursday, March 8th. This is a positive change from Shire's previous dividend of $3.85. The official announcement can be seen at this link. View Shire's Dividend History.

What price target have analysts set for SHP?

20 brokers have issued twelve-month price targets for Shire's stock. Their forecasts range from GBX 3,559 to GBX 8,000. On average, they anticipate Shire's stock price to reach GBX 4,600.75 in the next twelve months. View Analyst Ratings for Shire.

Who are some of Shire's key competitors?

Who are Shire's key executives?

Shire's management team includes the folowing people:
  • Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
  • Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
  • Gisele Dion, Chief Accounting Officer
  • Mr. Matthew Walker, Head of Technical Operations (Age 54)
  • Prof. Andreas Busch Ph.D., Head of R&D & Chief Scientific Officer (Age 55)

Has Shire been receiving favorable news coverage?

Media stories about SHP stock have been trending somewhat positive recently, according to Accern Sentiment. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Shire earned a news sentiment score of 0.01 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 45.81 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Shire?

Shares of SHP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Shire's stock price today?

One share of SHP stock can currently be purchased for approximately GBX 4,199.

How big of a company is Shire?

Shire has a market capitalization of £29.14 billion.

How can I contact Shire?

Shire's mailing address is Miesian Plaza 50-58 Baggot Street Lower, Block 2, DUBLIN, D02 HW68, Ireland. The biopharmaceutical company can be reached via phone at +353-1-6096000.


MarketBeat Community Rating for Shire (SHP)

Community Ranking:  4.0 out of 5 (star star star star)
Outperform Votes:  1,264 (Vote Outperform)
Underperform Votes:  299 (Vote Underperform)
Total Votes:  1,563
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Shire (LON:SHP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
20 Wall Street analysts have issued ratings and price targets for Shire in the last 12 months. Their average twelve-month price target is GBX 4,600.75The high price target for SHP is GBX 8,000 and the low price target for SHP is GBX 3,559. There are currently 4 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.852.852.882.89
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
15 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
15 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
13 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: GBX 4,600.75GBX 4,573.30GBX 5,243.75GBX 5,344.12

Shire (LON:SHP) Consensus Price Target History

Price Target History for Shire (LON:SHP)

Shire (LON:SHP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/11/2018Kepler Capital MarketsUpgradeBuyGBX 4,550View Rating Details
5/9/2018Deutsche BankReiterated RatingBuyView Rating Details
5/8/2018Liberum CapitalReiterated RatingHoldView Rating Details
5/8/2018Berenberg BankReiterated RatingBuyView Rating Details
5/8/2018Shore CapitalLower Price TargetBuyGBX 4,025 ➝ GBX 3,856View Rating Details
5/4/2018Credit Suisse GroupReiterated RatingOutperformView Rating Details
4/25/2018Royal Bank of CanadaReiterated RatingOutperformView Rating Details
4/20/2018CfraSet Price TargetBuyGBX 4,500View Rating Details
4/9/2018BNP ParibasReiterated RatingOutperformGBX 4,700View Rating Details
4/4/2018Societe GeneraleSet Price TargetBuyGBX 7,500View Rating Details
4/3/2018Sanford C. BernsteinSet Price TargetBuyGBX 4,400View Rating Details
3/29/2018HSBCReiterated RatingHoldView Rating Details
3/28/2018Main First BankInitiated CoverageOutperformGBX 3,600View Rating Details
3/28/2018Jefferies GroupReiterated RatingBuyGBX 4,100View Rating Details
3/27/2018Morgan StanleyReiterated RatingOverweightGBX 4,700View Rating Details
3/26/2018Goldman SachsReiterated RatingConviction-BuyGBX 4,600View Rating Details
2/21/2018CitigroupReiterated RatingBuyGBX 5,500View Rating Details
2/20/2018JPMorgan ChaseDowngradeNeutralGBX 5,000 ➝ GBX 3,600View Rating Details
2/15/2018BarclaysReiterated RatingEqual weightGBX 3,650View Rating Details
1/29/2018InvestecReiterated RatingBuyGBX 8,000View Rating Details
8/4/2017Beaufort SecuritiesReiterated RatingLong Term BuyGBX 6,200 ➝ GBX 4,900View Rating Details
2/16/2017UBSReiterated RatingNeutralGBX 5,000View Rating Details
1/9/2017Bryan, Garnier & CoReiterated RatingBuyGBX 6,800View Rating Details
11/7/2016AlphaValueReiterated RatingBuyGBX 6,714View Rating Details
11/3/2016Bank of AmericaReiterated RatingBuyGBX 6,970View Rating Details
(Data available from 5/20/2016 forward)

Earnings

Dividends

Shire (LON:SHP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/14/2018GBX 21.460.67%3/8/20183/8/20184/24/2018
8/3/2017GBX 3.850.1%9/7/20179/7/201710/20/2017
2/16/2017GBX 20.640.43%3/9/20173/9/20174/25/2017
8/2/2016GBX 3.510.07%9/8/20169/8/201610/7/2016
2/11/2016GBX 15.320.44%3/10/20163/10/20164/12/2016
7/23/2015GBX 2.690.05%9/3/20159/3/201510/2/2015
7/18/2014GBX 2.240.04%9/3/20149/3/201410/3/2014
2/13/2014GBX 10.210.31%3/5/20143/5/20144/8/2014
(Data available from 1/1/2013 forward)

Insider Trades

Shire (LON SHP) Insider Trading and Institutional Ownership History

Insider Trading History for Shire (LON:SHP)

Shire (LON SHP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/14/2018Mark Clayton JarvisDirectorSell365,000GBX 0.06£219
12/19/2017Dominic BlakemoreInsiderBuy165GBX 3,790£6,253.50
9/29/2017Anne MintoInsiderBuy190GBX 3,785£7,191.50
8/22/2017Flemming OrnskovInsiderBuy8,400GBX 3,665£307,860
6/30/2017Dominic BlakemoreInsiderBuy152GBX 4,255£6,467.60
3/31/2017William BurnsInsiderBuy136GBX 4,742£6,449.12
12/16/2016Olivier BohuonInsiderBuy141GBX 4,528£6,384.48
9/30/2016Dominic BlakemoreInsiderBuy133GBX 5,010£6,663.30
6/30/2016Bohuon,OlivierInsiderBuy134GBX 4,463£5,980.42
3/31/2016Bohuon,OlivierInsiderBuy133GBX 3,908£5,197.64
2/15/2016Bohuon,OlivierInsiderBuy1,000GBX 3,552£35,520
2/12/2016Burns,WilliamInsiderBuy1,250GBX 3,563£44,537.50
12/18/2015Burns,WilliamInsiderBuy156GBX 4,457£6,952.92
9/30/2015Blakemore ,DominicInsiderBuy129GBX 4,498£5,802.42
6/30/2015Kappler,David JInsiderBuy126GBX 51.05GBX 6,432.30
3/31/2015Susan KilsbyInsiderBuy375GBX 5,327£19,976.25
12/19/2014Steven GillisInsiderBuy228GBX 4,654£10,611.12
10/30/2014Steven GillisInsiderBuy381GBX 4,098£15,613.38
(Data available from 1/1/2013 forward)

Headlines

Shire (LON SHP) News Headlines

Source:
DateHeadline
Biogen, Shire called out by FDA for gaming generic access ruleBiogen, Shire called out by FDA for 'gaming' generic access rule
www.bizjournals.com - May 17 at 6:10 PM
Takeda CEO Sees Path to Survival in Shire MegadealTakeda CEO Sees Path to Survival in Shire Megadeal
www.bloomberg.com - May 16 at 5:31 PM
Global Eating Disorders Market 2018-2028: Shire Leads Industry Sponsors with the Highest Number of Clinical TrialsGlobal Eating Disorders Market 2018-2028: Shire Leads Industry Sponsors with the Highest Number of Clinical Trials
www.prnewswire.com - May 14 at 5:14 PM
Is There An Opportunity With Shire plc’s (LON:SHP) 26% Undervaluation?Is There An Opportunity With Shire plc’s (LON:SHP) 26% Undervaluation?
finance.yahoo.com - May 14 at 5:14 PM
Shire (SHP) Lifted to "Buy" at Kepler Capital MarketsShire (SHP) Lifted to "Buy" at Kepler Capital Markets
www.americanbankingnews.com - May 11 at 9:53 AM
Shire (SHP) Lowered to "Under Review" at Kepler Capital MarketsShire (SHP) Lowered to "Under Review" at Kepler Capital Markets
www.americanbankingnews.com - May 10 at 2:19 PM
Whisky and Apologies Aided Takedas $62 Billion Gamble on ShireWhisky and Apologies Aided Takeda's $62 Billion Gamble on Shire
finance.yahoo.com - May 10 at 8:32 AM
Takedas Credit Rating Cut by Moodys on $62 Billion Shire DealTakeda's Credit Rating Cut by Moody's on $62 Billion Shire Deal
www.bloomberg.com - May 9 at 5:26 PM
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Shire plc And Encourages Investors To Contact The Firm For Additional InformationSHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Shire plc And Encourages Investors To Contact The Firm For Additional Information
finance.yahoo.com - May 9 at 5:26 PM
Shire (SHP) Rating Reiterated by Deutsche BankShire (SHP) Rating Reiterated by Deutsche Bank
www.americanbankingnews.com - May 9 at 8:52 AM
Takeda to takeover bigger rival Shire in $62bln dealTakeda to takeover bigger rival Shire in $62bln deal
www.usatoday.com - May 8 at 5:30 PM
Takeda Agrees to Buy Shire in Cash, Share DealTakeda Agrees to Buy Shire in Cash, Share Deal
www.bloomberg.com - May 8 at 5:30 PM
Oil pares losses after U.S. exits Iran deal, dollar off 2018 highsOil pares losses after U.S. exits Iran deal, dollar off 2018 highs
finance.yahoo.com - May 8 at 5:30 PM
Takeda aims to boost rare disease profile with Shire deal, says R&D chiefTakeda aims to boost rare disease profile with Shire deal, says R&D chief
finance.yahoo.com - May 8 at 5:30 PM
FTSE edges lower, but ends near 14-week high as oil’s drop offsets Shire stock rallyFTSE edges lower, but ends near 14-week high as oil’s drop offsets Shire stock rally
finance.yahoo.com - May 8 at 5:30 PM
Shire (SHP) Receives "Hold" Rating from Liberum CapitalShire (SHP) Receives "Hold" Rating from Liberum Capital
www.americanbankingnews.com - May 8 at 11:48 AM
Berenberg Bank Reiterates "Buy" Rating for Shire (SHP)Berenberg Bank Reiterates "Buy" Rating for Shire (SHP)
www.americanbankingnews.com - May 8 at 7:04 AM
Shore Capital Trims Shire (SHP) Target Price to GBX 3,856Shore Capital Trims Shire (SHP) Target Price to GBX 3,856
www.americanbankingnews.com - May 8 at 7:04 AM
Takeda closing in on ShireTakeda closing in on Shire
seekingalpha.com - May 7 at 5:30 PM
Shire (SHP) Receives Outperform Rating from Credit Suisse GroupShire (SHP) Receives Outperform Rating from Credit Suisse Group
www.americanbankingnews.com - May 5 at 1:07 AM
Shire plc : Director/PDMR ShareholdingShire plc : Director/PDMR Shareholding
finance.yahoo.com - May 1 at 5:11 PM
Shire (SHPG) Q1 Earnings Beat, Rare Disease Franchise StrongShire (SHPG) Q1 Earnings Beat, Rare Disease Franchise Strong
finance.yahoo.com - April 27 at 5:09 PM
Shire (SHP) Receives "Buy" Rating from Kepler Capital MarketsShire (SHP) Receives "Buy" Rating from Kepler Capital Markets
www.americanbankingnews.com - April 27 at 9:17 AM
BRIEF-Shire declines to comment on Takeda, any further disposalsBRIEF-Shire declines to comment on Takeda, any further disposals
www.reuters.com - April 26 at 5:11 PM
Shire Plc (SHPG) Q1 2018 Results - Earnings Call TranscriptShire Plc (SHPG) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 26 at 5:11 PM
Is Shire plc’s (LON:SHP) Balance Sheet A Threat To Its Future?Is Shire plc’s (LON:SHP) Balance Sheet A Threat To Its Future?
finance.yahoo.com - April 26 at 5:11 PM
Shires (SHP) Buy Rating Reiterated at Deutsche BankShire's (SHP) Buy Rating Reiterated at Deutsche Bank
www.americanbankingnews.com - April 26 at 10:08 AM
Shire (SHP) Receives Consensus Recommendation of "Buy" from AnalystsShire (SHP) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 26 at 9:38 AM
Shires (SHP) "Hold" Rating Reaffirmed at Liberum CapitalShire's (SHP) "Hold" Rating Reaffirmed at Liberum Capital
www.americanbankingnews.com - April 25 at 11:30 AM
Shires (SHP) "Outperform" Rating Reaffirmed at Royal Bank of CanadaShire's (SHP) "Outperform" Rating Reaffirmed at Royal Bank of Canada
www.americanbankingnews.com - April 25 at 10:42 AM
Shire (SHP) Price Target Raised to GBX 4,025Shire (SHP) Price Target Raised to GBX 4,025
www.americanbankingnews.com - April 25 at 9:22 AM
[$$] Takeda Nears Shire Deal as Japan Inc. Chases Growth Overseas[$$] Takeda Nears Shire Deal as Japan Inc. Chases Growth Overseas
finance.yahoo.com - April 25 at 8:28 AM
Shire willing to back $64 bln Takeda bid, market signals doubtsShire willing to back $64 bln Takeda bid, market signals doubts
finance.yahoo.com - April 25 at 8:28 AM
Shire, Takeda reach breakthrough in merger talks, says ReutersShire, Takeda reach breakthrough in merger talks, says Reuters
www.cnbc.com - April 24 at 5:29 PM
Amid a Boisterous Takeover, Shire Investor Meeting Keeps CalmAmid a Boisterous Takeover, Shire Investor Meeting Keeps Calm
www.bloomberg.com - April 24 at 5:29 PM
Shire receives yet another bid from Takeda as takeover deadline loomsShire receives yet another bid from Takeda as takeover deadline looms
www.cnbc.com - April 24 at 5:29 PM
Exclusive: Shire, Takeda reach breakthrough in deal talks - sourcesExclusive: Shire, Takeda reach breakthrough in deal talks - sources
finance.yahoo.com - April 24 at 5:29 PM
Shire Pops On Report A Takeover Deal With Takeda Is ImminentShire Pops On Report A Takeover Deal With Takeda Is Imminent
finance.yahoo.com - April 24 at 5:29 PM
Takenda Near Preliminary Agreement to Acquire Shire (SHPG) - BloombergTakenda Near Preliminary Agreement to Acquire Shire (SHPG) - Bloomberg
www.streetinsider.com - April 24 at 8:26 AM
Shire weighs fresh approach from Japans TakedaShire weighs fresh approach from Japan's Takeda
www.ft.com - April 24 at 8:26 AM
Form 8-K Shire plc For: Apr 23Form 8-K Shire plc For: Apr 23
www.streetinsider.com - April 23 at 5:07 PM
Shire plc : Holding(s) in CompanyShire plc : Holding(s) in Company
finance.yahoo.com - April 23 at 5:07 PM
Takeda Cant Kick Its Shire HabitTakeda Can't Kick Its Shire Habit
finance.yahoo.com - April 23 at 5:07 PM
Shire (SHPG) PT Raised to $186 at RBC Capital; Potential Deal to Overshadow ResultsShire (SHPG) PT Raised to $186 at RBC Capital; Potential Deal to Overshadow Results
www.streetinsider.com - April 23 at 8:21 AM
Shire (SHP) Rating Reiterated by Liberum CapitalShire (SHP) Rating Reiterated by Liberum Capital
www.americanbankingnews.com - April 20 at 6:56 PM
Shire (SHP) Rating Reiterated by Shore CapitalShire (SHP) Rating Reiterated by Shore Capital
www.americanbankingnews.com - April 20 at 6:54 PM
Shires (SHP) "Buy" Rating Reaffirmed at Deutsche BankShire's (SHP) "Buy" Rating Reaffirmed at Deutsche Bank
www.americanbankingnews.com - April 20 at 5:18 PM
Shire (SHP) Earns "Overweight" Rating from JPMorgan ChaseShire (SHP) Earns "Overweight" Rating from JPMorgan Chase
www.americanbankingnews.com - April 20 at 5:18 PM
Shire Pandemonium, Aluminum Glut, ZTE Fallout: CEO Daily for April 20, 2018Shire Pandemonium, Aluminum Glut, ZTE Fallout: CEO Daily for April 20, 2018
fortune.com - April 20 at 5:15 PM
Takeda increases bid for ShireTakeda increases bid for Shire
www.cnbc.com - April 20 at 5:15 PM

SEC Filings

Shire (LON:SHP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Shire (LON SHP) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.